



# CLAIMS


1. A fused pyrimidine derivative or a pharmaceutically acceptable salt thereof represented by Formula (I):




{wherein R¹ represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aromatic heterocyclic group; n represents an integer of 0 to 3; X¹ and X² may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aromatic heterocyclic group; and formula (II):



represents formula (III):



[wherein X--Y--Z represents  $R^2C=CR^3-NR^4$  (wherein  $R^2$ ,  $R^3$  and  $R^4$  may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aromatic heterocyclic group),  $R^2C=N-NR^4$  (wherein  $R^2$  and  $R^4$  have the same meanings as defined above, respectively),  $R^4N-CR^3=CR^2$  (wherein  $R^2$ ,  $R^3$  and  $R^4$  have the same meanings as defined above, respectively), or  $R^4N-N=CR^2$  (wherein  $R^2$  and  $R^4$  have the same meanings as defined above, respectively)] or formula (IV):



(IV)

[wherein Xa--Ya--Za represents  $R^2HC-NR^3-CHR^4$  (wherein  $R^2$ ,  $R^3$  and  $R^4$  have the same meanings as defined above, respectively),  $R^2HC-NR^3-NH$  (wherein  $R^2$  and  $R^3$  have the same meanings as defined above, respectively), or  $NH-NR^3-CHR^4$  (wherein  $R^3$  and  $R^4$  have the same meanings as defined above, respectively)]]].

2. The fused pyrimidine derivative or a pharmaceutically acceptable salt thereof according to claim 1, wherein  $R^1$  is substituted or unsubstituted lower alkyl.

3. The fused pyrimidine derivative or a pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein  $R^3$  is substituted or unsubstituted aryl, or substituted or

unsubstituted lower alkyl.

4. The fused pyrimidine derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, wherein  $X^1$  is substituted or unsubstituted aralkyl and  $X^2$  is a hydrogen atom.

5. A Pharmaceutical composition comprising the fused pyrimidine derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4 as an active ingredient.

6. A therapeutic agent for diabetes comprising the fused pyrimidine derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4 as an active ingredient.

7. A preventive and/or therapeutic agent for diabetic complications comprising the fused pyrimidine derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4 as an active ingredient.

8. A blood glucose-lowering agent comprising the fused pyrimidine derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4 as an active ingredient.

9. An insulin secretagogue comprising the fused pyrimidine derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4 as an active ingredient.

10. Use of the fused pyrimidine derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4 for a manufacture of a therapeutic agent for diabetes.

11. Use of the fused pyrimidine derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4 for a manufacture of a preventive and/or therapeutic agent for diabetic complications.

12. Use of the fused pyrimidine derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4 for a manufacture of a blood glucose-lowering agent.

13. Use of the fused pyrimidine derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4 for a manufacture of an insulin secretagogue.

14. A method for treating diabetes, which comprises administering an effective amount of the fused pyrimidine derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4.

15. A method for preventing and/or treating diabetic complications, which comprises administering an effective amount of the fused pyrimidine derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4.

16. A method for lowering blood glucose levels, which comprises administering an effective amount of the fused pyrimidine derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4.

17. A method for stimulating secretion of insulin, which comprises administering an effective amount of the fused pyrimidine derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4.